GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SCYX · Jun 30, 2026

SCYNEXIS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001178253-26-000027General Corporate
Operating cash generation0thOwn-history percentile · N=18
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-6334.04% · OPTIONAL · VALID

Revenue growth20thOwn-history percentile · N=15
Evidence method

Yoy · gp.fundamentals.revenue

-82.77% · CORE · VALID

Operating margin11thOwn-history percentile · N=18
Evidence method

Level · gp.fundamentals.operating_margin

-3308.51% · CORE · VALID

R&D intensity94thOwn-history percentile · N=18
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1655.74% · OPTIONAL · VALID

SBC intensity94thOwn-history percentile · N=18
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

241.70% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesSelf-history eligible
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20235/6 normalizedLevel 3Dec 31, 20235/6 normalizedLevel 3Mar 31, 20244/5 normalizedLevel 3Jun 30, 20244/5 normalizedLevel 3Sep 30, 20245/5 normalizedLevel 3Dec 31, 20245/5 normalizedLevel 3Mar 31, 20255/5 normalizedLevel 3Jun 30, 20255/5 normalizedLevel 3Sep 30, 20255/5 normalizedLevel 3Dec 31, 20255/5 normalizedLevel 3Jun 30, 20265/5 normalizedLevel 4
Period transition

What moved in the state?

Growth Increased
Previous
-100.00%
Current
-82.77%
Delta
17.23%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Mar 31, 2025
Similarity
95%
Compared
5 dimensions
Coverage
100%
Growth 0.0 · Profitability 4.0 · Sbc Intensity 5.6 · Cash Generation 7.1 · R And D Intensity 5.6
Sep 30, 2025
Similarity
88%
Compared
5 dimensions
Coverage
100%
Growth 21.7 · Profitability 7.6 · Sbc Intensity 0.7 · Cash Generation 12.5 · R And D Intensity 0.7
Jun 30, 2024
Similarity
74%
Compared
4 dimensions
Coverage
80%
Profitability 34.3 · Sbc Intensity 12.6 · Cash Generation 36.4 · R And D Intensity 5.6
Sep 30, 2023
Similarity
23%
Compared
4 dimensions
Coverage
80%
Profitability 63.9 · Sbc Intensity 69.4 · Cash Generation 100.0 · R And D Intensity 69.4
Research Graph

Related governed research

Analogous To · SCYX state analogue 4 →Analogous To · SCYX state analogue 2 →Compared To · Pharmaceutical Preparations peers →Analogous To · SCYX state analogue 1 →Analogous To · SCYX state analogue 3 →Has State · SCYNEXIS INC →Transitioned To · SCYX GROWTH_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.